NTT Precision Medicine

NTT Precision Medicine is a healthcare technology and data platform company established in July 2024 as the medical and healthcare arm of the NTT Group. The company focuses on advancing precision medicine and personalized healthcare in Japan by integrating genetic testing, digital health platforms, and real-world data (RWD). Its flagship offering, the Japan Precision Medicine Platform (JPP), aggregates clinical, laboratory, and genomic data from medical institutions to facilitate secure research collaboration with global pharmaceutical companies. Additionally, the company offers Genovision PGx, a pharmacogenomics genetic test developed in collaboration with RIKEN and A.D.A.M. Innovations to assess individual drug efficacy and adverse reaction risks.